Clinical trials: Insufficient Metabolic Control
Type 2 Diabetes
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- TERA 304 (NCT05504239)
- Testing
- Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Handok Inc.
Diabetes Mellitus, Type 2
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with…
- Trial name
- NCT01296412
- Testing
- sitagliptin, liraglutide, glimepiride
- Volunteers
- 653 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
This clincial trial is evaluating if the co-administration of saxagliptin and dapagliflozin, in addition to metformin, results in better glycemic control, as measured by HbA1c, over a treatment period of 52 weeks, compared to the…
- Trial name
- NCT02419612
- Testing
- Saxagliptin, Dapagliflozin, Glimepiride
- Where
- 84 sites in United States, Czechia and 8 more
- Volunteers
- 444 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients
This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and metformin in patients with diabetes mellitus.
- Trial name
- NCT01135433
- Testing
- ipragliflozin, metformin
- Where
- 7 sites in Japan
- Volunteers
- 168 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus
PPAR - Combination With Metformin
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Metformin Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic…
- Trial name
- NCT00162240
- Testing
- Muraglitazar
- Where
- 203 sites in United States, Argentina and 10 more
- Volunteers
- 534 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type II
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086515
- Testing
- Sitagliptin (MK0431), Metformin, Pioglitazone
- Volunteers
- 701 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
The objective of this study is to evaluate the efficacy and safety of dual add-on therapy with Gemigliptin 50 mg and Dapagliflozin 10 mg added to Metformin compared to add-on therapy with Gemigliptin 50 mg in combination with…
- Trial name
- NCT04255238
- Testing
- Gemigliptin 50mg, Dapagliflozin 10mg
- Volunteers
- 468 people
- Sponsor
- LG Chem
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
Primary Objective: To demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on diet and…
- Trial name
- NCT02926937
- Testing
- Sotagliflozin (SAR439954)
- Where
- 70 sites in United States, Canada and 1 more
- Volunteers
- 399 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes
Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in treatment-naïve subjects with type 2 diabetes who have inadequate glycaemic control with diet and exercise alone.
- Trial name
- NCT01257412
- Testing
- Dapagliflozin
- Where
- 15 sites in India
- Volunteers
- 375 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled on one or more…
- Trial name
- REVITALIZE 1 (NCT04419779)
- Testing
- Duodenal Mucosal Resurfacing (DMR)
- Where
- 58 sites in United States, Belgium and 5 more
- Volunteers
- 320 people
- Sponsor
- Fractyl Health Inc.
Type 1 Diabetes Mellitus
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
This study is designed to investigate the clinical efficacy and safety of pramlintide co-administered as a fixed-dose ratio with basal-bolus SC insulin, delivered simultaneously via 2 separate pumps, in subjects with type 1…
- Trial name
- NCT02500979
- Testing
- Pramlintide acetate, Lispro insulin U-100, Regular insulin U-100
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca